135 results about "Transdermal patch" patented technology

The invention relates to the field of cosmetics, in particular to a blue copper peptide composition with instantaneous cool feeling and infiltration promotion effects and a preparation method and application of the blue copper peptide composition. The composition comprises an active component copper-blue peptide and a cooling and permeation enhancing system formed by compounding at least two of menthane formylethylamine, menthone glyceryl ketal and methyl diisopropyl propionamide, and the active component can further comprise hexapeptide-11, a blue algae extract and a yeast fermentation product. The preparation method of the composition comprises three core steps of providing a water phase, adding the active ingredients and adding the cool and refreshing infiltration promoting system and other components. Through synergistic compounding of specific fresheners, on the premise that the use amount of each single component is remarkably reduced, efficient permeation promotion of the copper-blue peptide is achieved, the layered cool feeling experience which takes effect quickly and is lasting and mild is provided, the common skin irritation problem of a traditional permeation promoter or a high-concentration single freshener is avoided, and the effect is remarkable. And the transdermal patch has excellent transdermal efficiency, active matter stability and use comfort.

The objective of the present invention is to provide a dexmedetomidine transdermal composition and transdermal patch which are highly stable, non-irritating to the skin, significantly safe to be attached to the human body, and capable of achieving a sustained release effect for 2 to 5 days, as well as a method for preparing and using the same. [Solution] This application discloses a dexmedetomidine transdermal composition, a transdermal patch, and the preparation method and application thereof. The composition includes dexmedetomidine, propylene glycol, and a metal chelating crosslinker, or includes dexmedetomidine, propylene glycol, a metal chelating crosslinker, and a pressure-sensitive adhesive. In addition, this application adds propylene glycol as a solubilizing agent to the dexmedetomidine transdermal composition, which can reduce the generation of impurities and improve the compatibility of raw materials and auxiliary materials, and uses a metal chelating crosslinker and a pressure-sensitive adhesive together to jointly form the skeletal structure of the product, which significantly improves the adhesive performance and provides a better adhesion to patients.

The present invention provides a novel method for manufacturing a microstructure via the use of a viscous polymer, particularly microstructures that may be found on medical devices, such as transdermal patches, for either cosmetic or medicinal purposes.

1. Name of the product of this design: Packaging box (Melatonin Magnesium HETDS transdermal patch). 2. Purpose of this design product: used for product packaging. 3. The key design point of this product lies in the combination of pattern and color. 4. The picture or photo that best illustrates the key points of the design: Design 1 Stereoscopic Figure 1. 5. The design for which protection is sought includes color. 6. Designate Design 1 as the base design.

Systems, computer programs, devices, and methods that enable coordination across multiple devices of the mobile ecosystem. In one embodiment, smart glasses detect when a user is about to eat food or take a drink and capture the consumable and portion. The data is recorded in a "morsel track" for health activity analysis. Low-fidelity captures provide preliminary recognition, while higher-fidelity captures are selectively invoked for definitive classification. Machine-learning logic generates predicted metabolic responses, such as real-time glucose trends, based on the recorded events. Predicted responses may dynamically adjust the operation of continuous glucose monitors, heart-rate sensors, or other biomedical devices. In some embodiments, the system triggers a pharmaceutical dispenser, such as an insulin pump, inhaler, or transdermal patch, to provide closed-loop therapeutic intervention in real time.

The invention discloses a preparation method of a dumbbell array storage type hollow bacterial cellulose hydrogel transdermal patch, which comprises the following steps: uniformly mixing basic components of PDMS (Polydimethylsiloxane) with a curing agent to obtain a solution A; adding an organic solvent to obtain a solution B; adding ultrapure water to form a PDMS emulsion; pouring the PDMS emulsion on a mold, and heating and curing to obtain a PDMS sponge mold; performing static culture on the PDMS sponge mold on the bacterial liquid to obtain the bacterial cellulose hydrogel transdermal patch; putting the bacterial cellulose hydrogel transdermal patch into a NaOH solution, boiling, cooling to room temperature, and replacing the NaOH solution with deionized water until the pH is neutral, so as to obtain the dumbbell array storage type hollow bacterial cellulose hydrogel transdermal patch. According to the preparation method disclosed by the invention, the individualized dumbbell array storage type hollow bacterial cellulose hydrogel transdermal patch is synthesized through self-assembly of a PDMS sponge mold mediated bacterial interface, and the transdermal patch can be used for efficiently carrying drugs, slowly releasing for a long time and conformally attaching and is excellent in air permeability.

This invention belongs to the field of patch technology and relates to a sleep-aiding and hypnotic transdermal patch and its preparation method. The sleep-aiding and hypnotic transdermal patch includes a drug-loaded layer, which, by weight, comprises 2-9 parts of active drug and 0.1-7 parts of a penetration enhancer. The penetration enhancer is a combination of menthol and essential oil; the weight ratio of menthol to essential oil is 1-4:0.1-3. This invention, through optimizing the formulation and preparation process, successfully prepares a sleep-aiding and hypnotic transdermal patch with good permeability and stability, enabling slow release and absorption of the drug, solving the problems of insomnia and poor sleep quality; and reducing the probability of side effects while improving the therapeutic effect.

The invention belongs to the technical field of transdermal patches, and relates to a transdermal patch for improving the bioavailability of estradiol and a preparation method of the transdermal patch. The transdermal patch is prepared from the following components in percentage by weight: 5 to 21 percent of estradiol, 8 to 15 percent of polymer matrix, 0.5 to 1.5 percent of butylated hydroxytoluene, 10 to 15 percent of hydrogenated rosin glyceride, 2 to 5 percent of penetration enhancer, 3 to 8 percent of plasticizer and 25 to 35 percent of solvent. According to the transdermal patch disclosed by the invention, continuous and stable release of a medicine is realized, the transdermal absorption rate of estradiol is improved, so that the bioavailability is improved, the treatment effect is further improved, and meanwhile, the transdermal patch disclosed by the invention can also avoid a first-pass effect of the liver and reduce side effects; the transdermal drug delivery system is convenient to use, and the compliance of a patient is improved.

The invention discloses a transdermal patch containing lidocaine, the transdermal patch comprises a polymer matrix layer, the polymer matrix layer comprises active ingredients lidocaine, an acrylic acid pressure-sensitive adhesive and a penetration enhancer, the weight content of the lidocaine is 21-33%, the weight content of the acrylic acid pressure-sensitive adhesive is 45-75%, the weight content of the penetration enhancer is 1-10%, and the weight content of the penetration enhancer is 1-10%. The weight content of the penetration enhancer is 3%-25%. The transdermal patch disclosed by the invention is simple in prescription and process, good in drug permeability and colloid application performance and high in stability, can be continuously used for a long time without causing skin irritation, and is suitable for treating peripheral nerve related pains, especially patients requiring long-term administration such as post-herpes zoster neuralgia.

The present invention relates to a method (100) for preparing a transdermal patch (200). The method (100) achieves an accurate dosing of the drug, an accurate dispensing location, and an average distribution of the drug coating in the transdermal patch (200). The method (100) excludes heating and drying steps generally used in conventional transdermal patch preparation methods in order to maintain the quality of the drug in the transdermal patch (200). The invention also relates to said transdermal patch (200) for use in the treatment of wounds or scars, wherein said transdermal patch (200) comprises a backing film (220), a film layer (240) coated with said medicament, an adhesive layer (260) and a release liner (280). Preferably, the drug in the transdermal patch (200) comprises a synthetic formulation or a natural formulation with biological properties, depending on the desired treatment.

1. The name of the design product: transdermal patch (ion transdermal patch two). 2. The use of the design product: for protecting skin wounds. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: front view. 5. Other circumstances that need to be explained: the design product is a thin product, and the left view, right view, top view and bottom view are omitted.

The invention relates to an ibuprofen-containing transdermal patch as well as a preparation method and application thereof. The ibuprofen-containing transdermal patch comprises a polymer matrix layer, the polymer matrix layer comprises ibuprofen, a compound at least containing one amino group and a pressure-sensitive adhesive, and based on the weight of the polymer matrix layer, the ibuprofen accounts for 10-30% by weight, the compound at least containing one amino group accounts for 0.1-5% by weight, and the pressure-sensitive adhesive accounts for 0.1-5% by weight. The weight content of the pressure-sensitive adhesive is 45%-84%, the pressure-sensitive adhesive is composed of a silicone pressure-sensitive adhesive and an acrylate pressure-sensitive adhesive, and the weight ratio of the silicone pressure-sensitive adhesive to the acrylate pressure-sensitive adhesive is 1: 1-15: 1. According to the transdermal patch, the penetration capacity of ibuprofen is remarkably improved, particularly, the early-stage medicine penetration rate is higher, the medicine utilization rate is greatly improved, meanwhile, the patch is good in application performance, free of skin irritation, free of crystallization in the long-term storage process, good in stability and capable of better meeting the clinical medication requirement.

The invention relates to the technical field of traditional Chinese medicine external preparations, in particular to a defoaming agent and application thereof in the preparation process of a non-water transdermal system patch. The defoaming agent provided by the invention is obtained by mixing silicon dioxide and liquid paraffin according to a specific ratio and then heating. The silicon dioxide is used as a main defoaming component, and the liquid paraffin is helpful for uniformly dispersing the silicon dioxide in the hot melt colloid and enhancing the fluidity of the silicon dioxide, so that the breakage and discharge of bubbles are promoted, and the problem that the constitution of the paste is changed or the viscosity is reduced due to the addition of the defoaming agent is avoided. In a final non-aqueous transdermal system patch formula, a certain adding amount of the defoaming agent is controlled, so that bubbles can be effectively eliminated, and adverse effects on other physicochemical properties of the patch are avoided. According to the technical scheme, the technical problem that a large amount of foam is generated and is difficult to remove when the hot melt adhesive transdermal patch is subjected to adhesive melting, stirring and mixing operation under the high-temperature condition can be solved, and the hot melt adhesive transdermal patch has ideal popularization and application prospects.

The application discloses a transdermal patch special for children with dwarfism, and relates to the technical field of medical treatment, which comprises a patch main body and a needle cylinder, and a fixed plate is fixedly connected to the inside of the patch main body, and the top and the bottom of the fixed plate are penetrated by the needle cylinder; the top of the needle cylinder is provided with a pressing plate, the bottom of the pressing plate is provided with a stand column on the two sides of the needle cylinder, the bottom of the two stand columns is arranged in the inside of the fixed plate and is slidably connected with the fixed plate; the two stand columns are both sleeved with a spring one; the top of the pressing plate is provided with a clamping groove, the bottom of the clamping groove is communicated with the needle cylinder, and a clamping seat is arranged in the clamping groove; the top of the pressing plate is provided with a fence; the two sides of the pressing plate are both provided with a connecting rod, one end of the connecting rod is connected with the pressing plate, and the other end penetrates through the top of the patch main body; the two sides of the patch main body close to the bottom are both provided with a sticking layer; and the two sides of the inside of the patch main body are both provided with a negative pressure sponge layer. The burden of the children with dwarfism is relieved, growth hormone injection treatment is facilitated, and the skin redness and swelling caused after growth hormone injection can be effectively prevented and treated.

The invention discloses an immunosuppressant transdermal patch and a preparation method thereof, the transdermal patch is provided with a backing layer, an ointment-containing body and a protective layer, the backing layer is a polyester and ethylene-vinyl acetate copolymer film, the ointment-containing body is formed by mixing a main drug tacrolimus, a stabilizer, a matrix, a cross-linking agent and a pressure-sensitive adhesive, and the protective layer is a polyester and ethylene-vinyl acetate copolymer film. The protective layer is a polyethylene glycol terephthalate film, the protective layer is coated with the ointment-containing body, and then the backing layer is pressed and covered on the surface of the ointment-containing body. The immunosuppressant transdermal patch provided by the invention can be adhered to parts such as neck, shoulder, chest, arm memory and the like, can be freely adjusted in use duration according to different illness states, and is safe and free of toxic and side effects. In addition, the transdermal patch disclosed by the invention is good in stickiness, good in permeability, free of irritation and allergy phenomena, good in patient compliance and capable of being used for a long time. Meanwhile, the method has the advantages of low preparation cost, simple and reasonable preparation process and the like, and has wide application prospects.

The utility model discloses a transdermal patch recovery device, which relates to the technical field of transdermal patch recovery, and comprises two clamping plates, the two clamping plates are fixedly connected through a connecting plate, the connecting plate is provided with a limiting slot, the limiting slot is internally provided with a replacement recovery assembly, the replacement recovery assembly comprises a limiting strip inserted in the limiting slot, and the limiting strip is provided with a through hole. The top of the limiting strip is fixedly provided with a paster, one side of the paster is provided with a containing bag, an alcohol bag and a writing paper strip in an adhesive mode, one side of the containing bag is fixedly provided with a sealing cover, and one side of the sealing cover is connected with one side of the containing bag in an adhesive mode through adhesive sticker. The transdermal patch recovery device disclosed by the utility model is provided with the replacement and recovery assembly, so that the whole patch can be replaced in the use process, after patches in each batch are used up, the used pages can be taken down and replaced with new patches, the remaining pages can be continuously used, the taken new patches can be placed in the clamping plate again, and the replacement and recovery of the patches are facilitated. And a user can conveniently replace and mount.

A transdermal patch is provided, which comprises: a backing layer; a first drug-containing adhesive layer comprising a first nicotine or a pharmaceutically acceptable salt thereof and a first adhesive; a second drug-containing adhesive layer comprising a second nicotine or a pharmaceutically acceptable salt thereof and a second adhesive; and a release liner, wherein the first drug-containing adhesive layer and the second drug-containing adhesive layer is disposed between the backing layer and the release liner.

The present application relates to the field of medicine biology, and particularly relates to a transdermal patch containing dexmedetomidine. By adding a penetration enhancer, the transdermal rate and the permeation amount are improved, the onset time is shortened, the patch content is reduced, the skin residue is reduced, and the skin redness / scarring at the administration site caused by the accumulation of the drug in the skin is effectively avoided.

The invention relates to a transdermal patch combined with an electronic control system in the form of a smartwatch. The patch features a display that shows information about the current status and drug delivery. Simultaneously, electrical contacts within the patch enable the targeted delivery of active ingredients under the skin. The system reacts in real time to the patient's condition and can be used for various applications including insulin control, blood measurement and vacuum blood tests. The invention offers precise and needs-based control of drug delivery and enables continuous monitoring and adjustment based on the patient's current needs.

The invention discloses an ibuprofen transdermal patch based on core-shell structure viscous electrostatic spinning fibers and a preparation method of the ibuprofen transdermal patch, and belongs to the technical field of external transdermal patches. A viscous fiber membrane constructed based on core-shell structure electrospun fibers is used as a functional layer; a shell layer of the fibers is formed by curing a spinning solution formed by dissolving a thermoplastic elastomer and natural resin in an organic solvent B, and provides stable viscosity; the core layer is formed by curing a spinning solution formed by dissolving ibuprofen, a hydrophobic polymer and a penetration enhancer in an organic solvent A, and efficient loading and controllable release of drugs are achieved. By optimizing the shell-core flow rate ratio, spinning voltage and other key process parameters, the patch has the characteristics of strong adhesion in the initial stage and easy stripping in the later stage, and meanwhile, it is ensured that the transdermal permeation amount and release rate of the medicine meet the treatment requirements. The patch has the characteristics of high porosity and biphasic drug release which takes effect quickly in the initial stage and is maintained slowly in the subsequent stage, effectively avoids the first-pass effect and the skin irritation risk, and is particularly suitable for local treatment of inflammatory diseases such as acute gouty arthritis and the like.

An abuse deterrent and misuse deterrent transdermal patch comprising aversive agents incorporated in the backing layer of the patch. The aversive agents can exhibit biphasic or sustained kinetics of release with an immediate portion released rapidly and an extended portion released in a prolonged manner when exposed to a dissolution medium. The prolonged aversive agent release provides deterrence against extraction of drug from fresh and used patches and serves to prevent accidental misuse of used patches by children. The abuse deterrent and misuse deterrent patch systems can be used for transdermal delivery of therapeutically active agents and particularly those drugs that are highly prone to abuse such as opiate and opioid analgesics and stimulants.

The application discloses a sustained-release transdermal patch and a preparation process thereof, and particularly relates to the technical field of pharmaceutical preparations. The patch is a five-layer composite structure, and the key lies in that: the adhesive layer and the drug depot layer both contain ion pairs of clonidine and organic acid formed in situ under specific solvent and temperature conditions, and the formation of the ion pairs is confirmed by pH value or infrared spectrum; and specific transdermal penetration enhancers are further compounded, so that programmed controlled release is realized through the cooperation of the two layers. The preparation process adopts the sequence of forming ion pairs first and then mixing, realizes coating precision of ±2μm through slit extrusion coating combined with online thickness measurement closed-loop control, adopts gradient drying process with clear temperature zone, air speed and humidity parameters, and carries out real-time quality control based on the online near-infrared spectrum detection of the pre-established PLS regression model. The process can ensure that the patch realizes near-zero-order constant-speed release within 168h, and has the advantages of stable drug release, uniform content, stable quality and high batch consistency.

A transdermal patch for delivering lidocaine for pain relief comprises a backing layer, an adhesive layer, and a composition containing lidocaine in an amount ranging from about 1% to about 10% by weight and heparin as a non-anticoagulant permeation enhancer in an amount ranging from about 1% to about 50% by weight. The heparin enhances permeation of lidocaine through the skin without exerting systemic anticoagulant effects by temporarily disrupting lipid bilayers in the stratum corneum to create microchannels for increased diffusion of lidocaine molecules. The patch provides effective relief for multiple pain types including neuropathic pain, inflammatory pain, ischemic pain, post-surgical pain, nociplastic pain, mechanical pain, and compressive pain. The transdermal patch is configured to provide sustained release of lidocaine for periods ranging from about 8 hours to about 24 hours, reducing pain by at least 50% with minimal systemic absorption.

This invention provides a quality inspection device for transdermal patch production, belonging to the technical field of inspection equipment. It includes an electric chain conveyor, an air compressor, and also comprises an inspection mechanism, a control circuit, a thickness detection circuit, a trigger circuit, and a pushing mechanism. Multiple inspection mechanisms are included, each comprising a sleeve, spring, pressure sensor, movable rod, and bearing mounted together. A fixed frame is mounted on the upper end of the electric chain conveyor frame, and the sleeves of the three inspection mechanisms are respectively mounted on the lower end of the fixed frame. The pushing mechanism includes a cylinder and a push plate mounted together, with push ports at both ends of the frame. The cylinder barrel is mounted on the outside of one of the push ports. The control circuit, thickness detection circuit, and trigger circuit are installed in an electrical control box and electrically connected. When a product fails the quality inspection, the push plate automatically pushes it off the conveyor line into the defective product frame, thereby improving inspection efficiency and ensuring product quality.

The invention discloses a cinacalcet-containing transdermal patch as well as a preparation method and application thereof. The transdermal patch comprises a high-molecular matrix layer, wherein the high-molecular matrix layer comprises cinacalcet, a silicone pressure-sensitive adhesive and one or more high-molecular polymers selected from a water-insoluble cellulose derivative, polyvinylpyrrolidone and a polyethylene caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer. The transdermal patch disclosed by the invention is good in drug permeability and colloid application performance, high in safety, free of skin irritation, high in stability and good in uniformity, and can meet the requirements of clinically treating hyperparathyroidism or hypercalcemia.

This invention belongs to the field of pharmaceutical formulation technology, specifically disclosing a gastrodin transdermal patch and its preparation method. The patch consists of a backing layer, a drug-containing matrix layer, and an anti-adhesive layer, using gastrodin as the active ingredient. It employs HP-β-CD inclusion technology, combined with an HPMC and PVP polymer backbone and an oleic acid-menthol composite transdermal enhancement system. The preparation utilizes solvent casting and low-temperature vacuum drying processes, which are mild and controllable. This invention effectively solves the problems of difficult transdermal absorption, easy recrystallization, and low bioavailability of gastrodin. The resulting patch has excellent adhesion, no skin irritation, high transdermal penetration, and good skin biocompatibility. It can efficiently cross the blood-brain barrier, regulate the neuroinflammatory microenvironment in the brain, significantly inhibit the colonization and progression of non-small cell lung cancer brain metastases, and strongly reverse tumor-related anxiety and depression-like mood disorders. It provides a novel drug delivery regimen with great clinical translational potential for the non-invasive synergistic treatment of brain tumors and their associated mood disorders.

Article side polymers useful in the packaging of transdermal patches are disclosed. These films do not absorb skin permeation enhancers that are contained in transdermal patches including keto acids such as levulinic acid or sulfoxides such as an alkyl sulfoxide, e.g., dimethyl sulfoxide. Using such polymeric film, multilayer pouch constructions can be manufactured which include other polymeric layers, such as aluminum foil for moisture and oxygen barrier properties, polyester for tear resistance and paper layers for optimal printing and design.

The present application relates to a transdermal patch containing colchicine and a preparation method and use thereof. The transdermal patch comprises a matrix layer, wherein the matrix layer comprises an active ingredient colchicine, a hot melt pressure sensitive adhesive and optionally other pharmaceutically acceptable adjuvants, wherein the content of the colchicine is 0.1% to 5%, the content of the hot melt pressure sensitive adhesive is 1.9% to 99.9%, and the content of the other pharmaceutically acceptable adjuvants is 0% to 98% based on the total weight of the matrix layer. The transdermal patch containing colchicine of the present application has no local irritation during and after application, no gastrointestinal side effects, high patient compliance, strong drug permeability, good therapeutic effect, and can be used for preventing and / or treating gout and / or pericarditis.

1. The name of the design product: packaging box (transdermal patch). 2. The use of the design product: packaging for transdermal patch. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view.